Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy

International Journal of Urology

Volumn 19, Issue 12, 2012, Pages 1050-1057

  Kawashima, Atsunari ^a   Tsujimura, Akira ^a   Takayama, Hitoshi ^a   Arai, Yasuyuki ^b   Nin, Mikio ^c   Tanigawa, Go ^d   Uemura, Motohide ^a   Nakai, Yasutomo ^a   Nishimura, Kazuo ^b   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

^d OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

C reactive protein; Hyponatremia; Molecular targeted therapy; Prognostic factor; Renal cell carcinoma

Indexed keywords

SODIUM; SORAFENIB; SUNITINIB;

ACCURACY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; HAZARD RATIO; HUMAN; HYPONATREMIA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; SODIUM BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CONFIDENCE INTERVALS; FEMALE; HUMANS; HYPONATREMIA; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LEUKOCYTOSIS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEUTROPHILS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRROLES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SODIUM;

EID: 84870296775     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03115.x     Document Type: Article

References (38)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 2005; 353: 2477-90.
2. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 2006; 24: 5601-8.
3. Hudes G, Carducci M, Tomczak P etal. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
4. Motzer RJ, Escudier B, Oudard S etal. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
5. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20: 289-96.
6. Choueiri TK, Garcia JA, Elson P etal. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110: 543-50.
7. Heng DY, Xie W, Regan MM etal. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009; 27: 5794-9.
8. Kim WR, Biggins SW, Kremers WK etal. Hyponatremia and mortality among patients on the liver-transplant waiting list. N. Engl. J. Med. 2008; 359: 1018-26.
9. Gotsman I, Zwas D, Planer D etal. Clinical outcome of patients with heart failure and preserved left ventricular function. Am. J. Med. 2008; 121: 997-1001.
10. Nair V, Niederman MS, Masani N, Fishbane S. Hyponatremia in community-acquired pneumonia. Am. J. Nephrol. 2007; 27: 184-90.
11. Huo TI, Lin HC, Hsia CY etal. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig. Liver Dis. 2008; 40: 882-9.
12. Kim HS, Yi SY, Jun HJ etal. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 2007; 73: 192-7.
13. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J. Natl. Compr. Canc. Netw. 2006; 4: 631-8.
14. Vasudev NS, Brown JE, Brown SR etal. Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin. Cancer Res. 2008; 14: 1775-81.
15. Jeppesen AN, Jensen HK, Donskov F, Marcussen N, von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br. J. Cancer 2010; 102: 867-72.
16. Akaza H, Tsukamoto T, Fujioka T etal. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level. Jpn. J. Clin. Oncol. 2011; 41: 1023-30.
17. Greene FL. AJCC Cancer Staging Manual. Springer Verlag, Philadelphia, 2002.
18. Gore ME, Szczylik C, Porta C etal. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10: 757-63.
19. Matsuo S, Imai E, Horio M etal. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982-92.
20. Adrogue HJ, Madias NE. Hyponatremia. N. Engl. J. Med. 2000; 342: 1581-9.
21. Kumar S, Berl T. Sodium. Lancet 1998; 352: 220-8.
22. Sajadieh A, Binici Z, Mouridsen MR, Nielsen OW, Hansen JF, Haugaard SB. Mild hyponatremia carries a poor prognosis in community subjects. Am. J. Med. 2009; 122: 679-86.
23. Murakami T, Matoba H, Kuga Y, Ozawa S, Kubota K, Yoshida S. Hyponatremia in a patient with chronic inflammatory disease. Intern. Med. 1998; 37: 792-5.
24. Benrick A, Schele E, Pinnock SB etal. Interleukin-6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei. J. Neuroendocrinol. 2009; 21: 620-8.
25. Palin K, Moreau ML, Orcel H etal. Age-impaired fluid homeostasis depends on the balance of IL-6/IGF-I in the rat supraoptic nuclei. Neurobiol. Aging 2009; 30: 1677-92.
26. Hashizume M, Higuchi Y, Uchiyama Y, Mihara M. IL-6 plays an essential role in neutrophilia under inflammation. Cytokine 2011; 54: 92-9.
27. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J. Clin. Endocrinol. Metab. 1994; 79: 934-9.
28. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 2006; 13: 1365-70.
29. Karakiewicz PI, Hutterer GC, Trinh QD etal. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007; 110: 1241-7.
30. Saito K, Tatokoro M, Fujii Y etal. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur. Urol. 2009; 55: 1145-53.
31. Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int. 2011; 107: 1893-8.
32. Weber K, Doucet M, Kominsky S. Renal cell carcinoma bone metastasis - elucidating the molecular targets. Cancer Metastasis Rev. 2007; 26: 691-704.
33. Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res. 2011; 3: 177-89.
34. Gheorghiade M, Abraham WT, Albert NM etal. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur. Heart J. 2007; 28: 980-8.
35. Yokoyama H, Tanaka M. Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy? BJU Int. 2005; 95: 526-9.
36. Spital A. Diuretic-induced hyponatremia. Am. J. Nephrol. 1999; 19: 447-52.
37. Macfarlane R, Heng DY, Xie W etal. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 2011; 18: 365-70.
38. Ramsey S. The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer. Mol. Diagn. Ther. 2009; 13: 277-81.